{"preliminary_commentary":{"by_channel":{"x_thread":4,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"CheckMate 650","nct_id":"NCT02985957","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=checkmate-650-nct02985957. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"CheckMate 650","arms":[{"description":null,"label":"Cohort A (Arm A)","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort B (Arm B)","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort C (Arm C)","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort D (Arm D1)","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort D (Arm D2)","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort D (Arm D3)","type":"EXPERIMENTAL"},{"description":null,"label":"Cohort D (Arm D4)","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2025-01-07","type":"ACTUAL"},"conditions":["Prostate Cancer"],"enrollment":{"count":351,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Nivolumab","otherNames":["BMS-936558","Opdivo"],"type":"BIOLOGICAL"},{"name":"Ipilimumab","otherNames":["BMS-734016","Yervoy"],"type":"BIOLOGICAL"},{"name":"Cabazitaxel","otherNames":[],"type":"DRUG"},{"name":"Prednisone","otherNames":[],"type":"DRUG"}],"last_update":"2025-12-22","lead_sponsor":"Bristol-Myers Squibb","official_title":"A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2022-04-05","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) Cohorts B and C Per BICR","timeFrame":"From first dose to the date of objectively documented progression or the date of subsequent systemic anti-cancer therapy, whichever occurred first (assessed up to approximately 61 months)"},{"measure":"Objective Response Rate (ORR) Cohort D","timeFrame":"From randomization to the date of objectively documented progression or the date of subsequent systemic anti-cancer therapy, whichever occurred first (assessed up to approximately 61 months)"},{"measure":"Radiographic Progression Free Survival (rPFS) for Cohorts B and C Per BICR","timeFrame":"From first dose to the date of objectively documented progression or death due to any cause, whichever occurred first (assessed up to approximately 61 months)"},{"measure":"Radiographic Progression-Free Survival (rPFS) for Cohort D","timeFrame":"From randomization and the first date of documented progression or death due to any cause, whichever occurs first (assessed up to approximately 61 months)"}],"references":[{"citation":"Sharma P, Pachynski RK, Narayan V, Flechon A, Gravis G, Galsky MD, Mahammedi H, Patnaik A, Subudhi SK, Ciprotti M, Simsek B, Saci A, Hu Y, Han GC, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020 Oct 12;38(4):489-499.e3. doi: 10.1016/j.ccell.2020.08.007. Epub 2020 Sep 10.","pmid":"32916128","type":"DERIVED"}],"start_date":{"date":"2017-03-26","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)","url":"https://clinicaltrials.gov/study/NCT02985957"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/checkmate-650-nct02985957"}